Next Article in Journal
A Case for Tobacco Content Regulation by The U.S. Food and Drug Administration
Previous Article in Journal
Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue 4
10.3747/co.v17i4.696
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cetuximab in Locally Advanced Head-And-Neck Cancer: Defining the Population

by
C. Ho
BC Canc Agcy Vancouver, Vancouver, BC V5Z 4E6, Canada
Curr. Oncol. 2010, 17(4), 48-51; https://doi.org/10.3747/co.v17i4.696
Submission received: 9 May 2010 / Revised: 6 June 2010 / Accepted: 4 July 2010 / Published: 1 August 2010

Abstract

Encouraging data for targeted therapy in head-and-neck squamous cell carcinoma are opening new options for treatment. Phase III trials of cetuximab, an antibody directed against the epidermal growth factor receptor (EGFR) have demonstrated benefit in the locally advanced and metastatic settings. Recognizing the importance of emerging therapies, Cancer Care Ontario published guideline recommendations for EGFR-targeted therapy in stage III and IV head-and-neck cancer. The present paper takes a further look at the population for whom an offer of cetuximab therapy may be appropriate.
Keywords: head-and-neck squamous cell carcinoma; locally advanced; cisplatin; cetuximab; radiotherapy head-and-neck squamous cell carcinoma; locally advanced; cisplatin; cetuximab; radiotherapy

Share and Cite

MDPI and ACS Style

Ho, C. Cetuximab in Locally Advanced Head-And-Neck Cancer: Defining the Population. Curr. Oncol. 2010, 17, 48-51. https://doi.org/10.3747/co.v17i4.696

AMA Style

Ho C. Cetuximab in Locally Advanced Head-And-Neck Cancer: Defining the Population. Current Oncology. 2010; 17(4):48-51. https://doi.org/10.3747/co.v17i4.696

Chicago/Turabian Style

Ho, C. 2010. "Cetuximab in Locally Advanced Head-And-Neck Cancer: Defining the Population" Current Oncology 17, no. 4: 48-51. https://doi.org/10.3747/co.v17i4.696

APA Style

Ho, C. (2010). Cetuximab in Locally Advanced Head-And-Neck Cancer: Defining the Population. Current Oncology, 17(4), 48-51. https://doi.org/10.3747/co.v17i4.696

Article Metrics

Back to TopTop